Stabilized helical peptides: overview of the technologies and its impact on drug discovery

References

• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–208.
   PubMed Web of Science ®Google Scholar
• Estieu-Gionnet K, Guichard G. Stabilized helical peptides: overview of the technologies and therapeutic promises. Expert Opin Drug Discov. 2011;6:937–963.
   PubMed Web of Science ®Google Scholar
• Stumpf MP, Thorne T, de Silva E, et al. Estimating the size of the human interactome. Proc Natl Acad Sci USA. 2008;105:6959–6964.
   PubMed Web of Science ®Google Scholar
• Rezaei Araghi R, Keating AE. Designing helical peptide inhibitors of protein-protein interactions. Curr Opin Struct Biol. 2016;39:27–38.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in advanced Melanoma. N Engl J Med. 2015;372:2521–2532.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated Melanoma. N Engl J Med. 2015;373:23–34.
   PubMed Web of Science ®Google Scholar
• Cromm PM, Spiegel J, Grossmann TN. Hydrocarbon stapled peptides as modulators of biological function. ACS Chem Biol. 2015;10:1362–1375.
   PubMed Web of Science ®Google Scholar
• Bird GH, Gavathiotis E, LaBelle JL, et al. Distinct BimBH3 (BimSAHB) stapled peptides for structural and cellular studies. ACS Chem Biol. 2014;9:831–837.
   PubMed Web of Science ®Google Scholar
• Walensky LD, Bird GH. Hydrocarbon-stapled peptides: principles, practice, and progress. J Med Chem. 2014;57:6275–6288.
   PubMed Web of Science ®Google Scholar
• Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:600–606.
   PubMed Web of Science ®Google Scholar
• Horne WS. Peptide and peptoid foldamers in medicinal chemistry. Expert Opin Drug Discov. 2011;6:1247–1262.
   PubMed Web of Science ®Google Scholar
• Hegedus Z, Weber E, Kriston-Pal E, et al. Foldameric alpha/beta-peptide analogs of the beta-sheet-forming antiangiogenic anginex: structure and bioactivity. J Am Chem Soc. 2013;135:16578–16584.
   PubMed Web of Science ®Google Scholar
• Checco JW, Gellman SH. Targeting recognition surfaces on natural proteins with peptidic foldamers. Curr Opin Struct Biol. 2016;39:96–105.
   PubMed Web of Science ®Google Scholar
• Joy ST, Arora PS. An optimal hydrogen-bond surrogate for alpha-helices. Chem Commun (Camb). 2016;52:5738–5741.
   PubMed Web of Science ®Google Scholar
• Schafmeister CE, Po J, Verdine GL. An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J Am Chem Soc. 2000;122:5891–5892.
   Web of Science ®Google Scholar
• Walensky LD, Kung AL, Escher I, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science. 2004;305:1466–1470.
   PubMed Web of Science ®Google Scholar
• Hilinski GJ, Kim YW, Hong J, et al. Stitched alpha-helical peptides via bis ring-closing metathesis. J Am Chem Soc. 2014;136:12314–12322.
   PubMed Web of Science ®Google Scholar
• Bao J, Dong XY, Zhang JZ, et al. Dynamical binding of hydrogen-bond surrogate derived Bak helices to antiapoptotic protein Bcl-xL. J Phys Chem B. 2009;113:3565–3571.
   PubMed Web of Science ®Google Scholar
• Chapman RN, Dimartino G, Arora PS. A highly stable short alpha-helix constrained by a main-chain hydrogen-bond surrogate. J Am Chem Soc. 2004;126:12252–12253.
   PubMed Web of Science ®Google Scholar
• Dimartino G, Wang D, Chapman RN, et al. Solid-phase synthesis of hydrogen-bond surrogate-derived alpha-helices. Org Lett. 2005;7:2389–2392.
   PubMed Web of Science ®Google Scholar
• Mahon AB, Arora PS. Design, synthesis and protein-targeting properties of thioether-linked hydrogen bond surrogate helices. Chem Commun (Camb). 2012;48:1416–1418.
   PubMed Web of Science ®Google Scholar
• Miller SE, Thomson PF, Arora PS. Synthesis of hydrogen-bond surrogate alpha-helices as inhibitors of protein-protein interactions. Curr Protoc Chem Biol. 2014;6:101–116.
   PubMedGoogle Scholar
• Patgiri A, Jochim AL, Arora PS. A hydrogen bond surrogate approach for stabilization of short peptide sequences in alpha-helical conformation. Acc Chem Res. 2008;41:1289–1300.
   PubMed Web of Science ®Google Scholar
• Patgiri A, Witten MR, Arora PS. Solid phase synthesis of hydrogen bond surrogate derived alpha-helices: resolving the case of a difficult amide coupling. Org Biomol Chem. 2010;8:1773–1776.
   PubMed Web of Science ®Google Scholar
• Wang D, Chen K, Dimartino G, et al. Nucleation and stability of hydrogen-bond surrogate-based alpha-helices. Org Biomol Chem. 2006;4:4074–4081.
   PubMed Web of Science ®Google Scholar
• Gellman SH. Foldamers: a manifesto. Acc Chem Res. 1998;31:173–180.
   Web of Science ®Google Scholar
• Horne WS, Boersma MD, Windsor MA, et al. Sequence-based design of alpha/beta-peptide foldamers that mimic BH3 domains. Angew Chem Int Ed Engl. 2008;47:2853–2856.
   PubMed Web of Science ®Google Scholar
• Werner HM, Horne WS. Folding and function in alpha/beta-peptides: targets and therapeutic applications. Curr Opin Chem Biol. 2015;28:75–82.
   PubMed Web of Science ®Google Scholar
• Johnson LM, Gellman SH. Alpha-helix mimicry with alpha/beta-peptides. Methods Enzymol. 2013;523:407–429.
   PubMed Web of Science ®Google Scholar
• Karle IL, Flippen-Anderson J, Sukumar M, et al. Conformation of a 16-residue zervamicin IIA analog peptide containing three different structural features: 3(10)-helix, alpha-helix, and beta-bend ribbon. Proc Natl Acad Sci USA. 1987;84:5087–5091.
   PubMed Web of Science ®Google Scholar
• Karle IL, Sukumar M, Balaram P. Parallel packing of alpha-helices in crystals of the zervamicin IIA analog Boc-Trp-Ile-Ala-Aib-Ile-Val-Aib-Leu-Aib-Pro-OMe.2H2O. Proc Natl Acad Sci USA. 1986;83:9284–9288.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev. 1997;23:3–25.
   Web of Science ®Google Scholar
• Wei SJ, Chee S, Yurlova L, et al. Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides. Oncotarget. 2016;7:32232–32246.
   PubMed Web of Science ®Google Scholar
• Bird GH, Madani N, Perry AF, et al. Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc Natl Acad Sci USA. 2010;107:14093–14098.
   PubMed Web of Science ®Google Scholar
• Wang D, Liao W, Arora PS. Enhanced metabolic stability and protein-binding properties of artificial alpha helices derived from a hydrogen-bond surrogate: application to Bcl-xL. Angew Chem Int Ed Engl. 2005;44:6525–6529.
   PubMed Web of Science ®Google Scholar
• Checco JW, Lee EF, Evangelista M, et al. Alpha/beta-peptide foldamers targeting intracellular protein-protein interactions with activity in living cells. J Am Chem Soc. 2015;137:11365–11375.
   PubMed Web of Science ®Google Scholar
• Bernal F, Tyler AF, Korsmeyer SJ, et al. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc. 2007;129:2456–2457.
   PubMed Web of Science ®Google Scholar
• Bird GH, Mazzola E, Opoku-Nsiah K, et al. Biophysical determinants for cellular uptake of hydrocarbon-stapled peptide helices. Nat Chem Biol. 2016;12:845–852.
   PubMed Web of Science ®Google Scholar
• Bird GH, Crannell WC, Walensky LD. Chemical synthesis of hydrocarbon-stapled peptides for protein interaction research and therapeutic targeting. Curr Protoc Chem Biol. 2011;3:99–117.
   PubMedGoogle Scholar
• Sun TL, Sun Y, Lee CC, et al. Membrane permeability of hydrocarbon-cross-linked peptides. Biophys J. 2013;104:1923–1932.
   PubMed Web of Science ®Google Scholar
• Tan YS, Lane DP, Verma CS. Stapled peptide design: principles and roles of computation. Drug Discov Today. 2016;21:1642–1653.
   PubMed Web of Science ®Google Scholar
• Lama D, Quah ST, Verma CS, et al. Rational optimization of conformational effects induced by hydrocarbon staples in peptides and their binding interfaces. Sci Rep. 2013;3:3451.
   PubMed Web of Science ®Google Scholar
• Gavathiotis E, Suzuki M, Davis ML, et al. BAX activation is initiated at a novel interaction site. Nature. 2008;455:1076–1081.
   PubMed Web of Science ®Google Scholar
• Modi V, Lama D, Sankararamakrishnan R. Relationship between helix stability and binding affinities: molecular dynamics simulations of Bfl-1/A1-binding pro-apoptotic BH3 peptide helices in explicit solvent. J Biomol Struct Dyn. 2013;31:65–77.
   PubMed Web of Science ®Google Scholar
• Rezaei Araghi R, Ryan JA, Letai A, et al. Rapid optimization of Mcl-1 inhibitors using stapled peptide libraries including non-natural side chains. ACS Chem Biol. 2016;11:1238–1244.
   PubMed Web of Science ®Google Scholar
• Klein MA. Stabilized helical peptides: a strategy to target protein-protein interactions. ACS Med Chem Lett. 2014;5:838–839.
   PubMed Web of Science ®Google Scholar
• Ferreira LG, Dos Santos RN, Oliva G, et al. Molecular docking and structure-based drug design strategies. Molecules. 2015;20:13384–13421.
   PubMed Web of Science ®Google Scholar
• Kutchukian PS, Yang JS, Verdine GL, et al. All-atom model for stabilization of alpha-helical structure in peptides by hydrocarbon staples. J Am Chem Soc. 2009;131:4622–4627.
   PubMed Web of Science ®Google Scholar
• Pechenov S, Bhattacharjee H, Yin D, et al. Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery. Adv Drug Deliv Rev. 2017;112:106–122.
   PubMed Web of Science ®Google Scholar
• Cheloha RW, Maeda A, Dean T, et al. Backbone modification of a polypeptide drug alters duration of action in vivo. Nat Biotechnol. 2014;32:653–655.
   PubMed Web of Science ®Google Scholar
• Zhao D, Tahaney WM, Mazumdar A, et al. Molecularly targeted therapies for p53-mutant cancers. Cell Mol Life Sci. 2017.
   Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991;253:49–53.
   PubMed Web of Science ®Google Scholar
• Bernal F, Wade M, Godes M, et al. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell. 2010;18:411–422.
   PubMed Web of Science ®Google Scholar
• Henchey LK, Porter JR, Ghosh I, et al. High specificity in protein recognition by hydrogen-bond-surrogate alpha-helices: selective inhibition of the p53/MDM2 complex. Chembiochem. 2010;11:2104–2107.
   PubMed Web of Science ®Google Scholar
• Wachter F, Morgan AM, Godes M, et al. Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting. Oncogene. 2017;36:2184–2190.
   PubMed Web of Science ®Google Scholar
• Patgiri A, Joy ST, Arora PS. Nucleation effects in peptide foldamers. J Am Chem Soc. 2012;134:11495–11502.
   PubMed Web of Science ®Google Scholar
• Peterson-Kaufman KJ, Haase HS, Boersma MD, et al. Residue-based preorganization of BH3-derived alpha/beta-peptides: modulating affinity, selectivity and proteolytic susceptibility in alpha-helix mimics. ACS Chem Biol. 2015;10:1667–1675.
   PubMed Web of Science ®Google Scholar
• Boersma MD, Haase HS, Peterson-Kaufman KJ, et al. Evaluation of diverse alpha/beta-backbone patterns for functional alpha-helix mimicry: analogues of the Bim BH3 domain. J Am Chem Soc. 2012;134:315–323.
   PubMed Web of Science ®Google Scholar
• Edwards AL, Wachter F, Lammert M, et al. Cellular uptake and ultrastructural localization underlie the pro-apoptotic activity of a hydrocarbon-stapled BIM BH3 peptide. ACS Chem Biol. 2015;10:2149–2157.
   PubMed Web of Science ®Google Scholar
• Moellering RE, Cornejo M, Davis TN, et al. Direct inhibition of the NOTCH transcription factor complex. Nature. 2009;462:182–188.
   PubMed Web of Science ®Google Scholar
• Campbell RM, Tummino PJ. Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Invest. 2014;124:64–69.
   PubMed Web of Science ®Google Scholar
• Kim W, Bird GH, Neff T, et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol. 2013;9:643–650.
   PubMed Web of Science ®Google Scholar
• Avdulov S, Herrera J, Smith K, et al. eIF4E threshold levels differ in governing normal and neoplastic expansion of mammary stem and luminal progenitor cells. Cancer Res. 2015;75:687–697.
   PubMed Web of Science ®Google Scholar
• Bitterman PB, Polunovsky VA. eIF4E-mediated translational control of cancer incidence. Biochim Biophys Acta. 2015;1849:774–780.
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Saleh MN, Infante JR, et al. Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas. J Clin Oncol. 2017;35:2505.
   Web of Science ®Google Scholar